Axsome's sleep disorder drug succeeds in late-stage trial, shares rise

Axsome Therapeutics (AXSM.O) said on Monday its experimental therapy cut the frequency of disruptive episodes of muscle weakness tied to a sleep disorder called narcolepsy in a late-stage trial.